STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish
STAT
DECEMBER 15, 2023
million price tag is nearly $1 million higher than its rivals’, even though its own treatment has a serious safety warning about a blood cancer risk. Pfizer overestimated future demand for its pandemic products. And Pfizer’s other products, no matter how promising, could not close the gap.
Let's personalize your content